Login to Your Account

Financings Roundup

Ready for 'Pivotal' Year, Array Adds $52M in Public Offering

By Jennifer Boggs
Managing Editor

Friday, February 10, 2012
With data from at least seven clinical trials due this year, along with a Phase III go/no-go decision on its most advanced partnered program, Array Biopharma Inc. is bolstering its cash position with a $52 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription